A detailed history of Childress Capital Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Childress Capital Advisors, LLC holds 1,895 shares of AMGN stock, worth $501,208. This represents 0.17% of its overall portfolio holdings.

Number of Shares
1,895
Previous 1,982 4.39%
Holding current value
$501,208
Previous $619,000 1.45%
% of portfolio
0.17%
Previous 0.18%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$309.38 - $337.38 $26,916 - $29,352
-87 Reduced 4.39%
1,895 $610,000
Q2 2024

Aug 05, 2024

BUY
$262.75 - $319.31 $24,698 - $30,015
94 Added 4.98%
1,982 $619,000
Q1 2024

Apr 24, 2024

SELL
$268.87 - $324.56 $29,037 - $35,052
-108 Reduced 5.41%
1,888 $536,000
Q4 2023

Feb 16, 2024

BUY
$255.7 - $288.46 $511 - $576
2 Added 0.1%
1,996 $574,000
Q3 2023

Nov 06, 2023

BUY
$218.65 - $271.46 $435,988 - $541,291
1,994 New
1,994 $535,000
Q4 2022

Feb 03, 2023

SELL
$229.03 - $291.01 $69,396 - $88,176
-303 Reduced 13.13%
2,005 $526,000
Q3 2022

Nov 03, 2022

BUY
$224.46 - $253.15 $19,752 - $22,277
88 Added 3.96%
2,308 $536,000
Q2 2022

Aug 15, 2022

BUY
$230.71 - $256.74 $29,069 - $32,349
126 Added 6.02%
2,220 $540,000
Q1 2022

May 10, 2022

BUY
$219.27 - $242.57 $39,907 - $44,147
182 Added 9.52%
2,094 $507,000
Q4 2021

Jan 26, 2022

BUY
$198.88 - $227.6 $56,084 - $64,183
282 Added 17.3%
1,912 $430,000
Q3 2021

Nov 15, 2021

BUY
$212.27 - $248.7 $11,038 - $12,932
52 Added 3.3%
1,630 $352,000
Q2 2021

Jul 28, 2021

SELL
$233.58 - $259.14 $130,104 - $144,340
-557 Reduced 26.09%
1,578 $384,000
Q1 2021

May 21, 2021

BUY
$221.91 - $258.6 $149,345 - $174,037
673 Added 46.03%
2,135 $531,000
Q4 2020

Mar 09, 2021

BUY
$216.38 - $257.67 $316,347 - $376,713
1,462 New
1,462 $336,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Childress Capital Advisors, LLC Portfolio

Follow Childress Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Childress Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Childress Capital Advisors, LLC with notifications on news.